TRCT
XENE icon

Tower Research Capital (TRC)’s Xenon Pharmaceuticals XENE Stock Holding History

Tower Research Capital (TRC)’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$355K Buy
6,105
+2,873
+89% +$132K 0.01% 1181
2025
Q4 		$145K Buy
3,232
+1,715
+113% +$72K ﹤0.01% 1691
2025
Q3 		$60.9K Sell
1,517
-3,840
-72% -$135K ﹤0.01% 2365
2025
Q2 		$168K Buy
5,357
+5,307
+10,614% +$173K ﹤0.01% 1951
2025
Q1 		$1.68K Sell
50
-597
-92% -$22.7K ﹤0.01% 4670
2024
Q4 		$25.4K Sell
647
-1,372
-68% -$56.7K ﹤0.01% 3012
2024
Q3 		$79.5K Sell
2,019
-6,208
-75% -$250K ﹤0.01% 2414
2024
Q2 		$321K Buy
8,227
+7,001
+571% +$280K 0.01% 1712
2024
Q1 		$52.8K Buy
1,226
+212
+21% +$9.75K ﹤0.01% 2240
2023
Q4 		$46.7K Buy
1,014
+817
+415% +$28.9K ﹤0.01% 3173
2023
Q3 		$6.73K Sell
197
-5,327
-96% -$199K ﹤0.01% 4564
2023
Q2 		$213K Buy
5,524
+5,013
+981% +$199K 0.01% 1517
2023
Q1 		$18K Sell
511
-2,041
-80% -$75.4K ﹤0.01% 3591
2022
Q4 		$101K Sell
2,552
-1,648
-39% -$60K ﹤0.01% 1840
2022
Q3 		$151K Buy
4,200
+2,738
+187% +$98.4K ﹤0.01% 2193
2022
Q2 		$44K Hold
1,462
– – ﹤0.01% 3025
2022
Q1 		$44K Buy
1,462
+816
+126% +$24.4K ﹤0.01% 2842
2021
Q4 		$20K Sell
646
-667
-51% -$19.9K ﹤0.01% 3692
2021
Q3 		$20K Buy
1,313
+924
+238% +$16.1K ﹤0.01% 3731
2021
Q2 		$7K Sell
389
-16
-4% -$295 ﹤0.01% 4572
2021
Q1 		$7K Sell
405
-943
-70% -$16K ﹤0.01% 4551
2020
Q4 		$21K Buy
1,348
+636
+89% +$7.44K ﹤0.01% 3849
2020
Q3 		$8K Buy
+712
New +$8.38K ﹤0.01% 4199
2020
Q2 		– Sell
-1,450
Closed -$16K – 5031
2020
Q1 		$16K Sell
1,450
-3,556
-71% -$50.6K ﹤0.01% 1830
2019
Q4 		$65K Buy
5,006
+2,004
+67% +$21.1K 0.01% 1176
2019
Q3 		$27K Buy
+3,002
New +$28.4K ﹤0.01% 2276
2019
Q2 		– Sell
-1,870
Closed -$19K – 4385
2019
Q1 		$19K Buy
1,870
+1,606
+608% +$13.6K ﹤0.01% 2305
2018
Q4 		$2K Buy
264
+164
+164% +$1.46K ﹤0.01% 3455
2018
Q3 		$1K Buy
+100
New +$1.16K ﹤0.01% 3636
2017
Q4 		– Sell
-325
Closed -$1K – 4080
2017
Q3 		$1K Sell
325
-3,330
-91% -$10.3K ﹤0.01% 3682
2017
Q2 		$11K Buy
+3,655
New +$14.3K ﹤0.01% 1588
2016
Q4 		– Sell
-997
Closed -$8K – 4472
2016
Q3 		$8K Buy
997
+111
+13% +$857 ﹤0.01% 2237
2016
Q2 		$6K Sell
886
-1,458
-62% -$10K ﹤0.01% 3303
2016
Q1 		$17K Buy
2,344
+1,075
+85% +$7.73K ﹤0.01% 1485
2015
Q4 		$10K Buy
1,269
+334
+36% +$2.86K ﹤0.01% 2157
2015
Q3 		$8K Buy
935
+835
+835% +$8.29K ﹤0.01% 2495
2015
Q2 		$1K Buy
+100
New +$1.38K ﹤0.01% 4098

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tower Research Capital (TRC)'s XENE Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Xenon Pharmaceuticals (XENE) stake by 89% in Q1 2026, buying an estimated $132K and bringing the position to 6,105 shares worth $355K. The position accounts for 0.01% of the portfolio, ranked #1181.

Tower Research Capital (TRC) first reported a position in XENE in Q2 2015 and has held it in 37 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Tower Research Capital (TRC) held 6,105 shares of Xenon Pharmaceuticals worth $355K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,873 Xenon Pharmaceuticals shares in Q1 2026, an estimated $132K.
  • Xenon Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1181 holding.
  • Tower Research Capital (TRC) first reported a position in Xenon Pharmaceuticals in Q2 2015 and has held it in 37 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.